Authors&apos reply: Benefit and risks of trivalent 2010 seasonal influenza vaccine in Australian children

摘要

Dr Lopert from Australia’s regulatory body for therapeutic goods, the Therapeutics Goods Administration (TGA), raises a number of issues about our quantification of the risk-benefit ratio for seasonal trivalent influenza vaccines administered to children aged six months to four years in Australia in 2010 [1]. While we continue to believe the current data support vaccination of healthy children, it is important to con- duct robust post-marketing surveillance, support an open scientific discussion of the observations, and ensure a rapid, comprehensive response to any poten- tial adverse events following immunisation (AEFI).